Most monoclonal antibodies to poliovirus 3 but not poliovirus 1 require a single 12-amino-acid sequence in virion protein VP1 for neutralization (site 1). None of the available monoclonal antibodies requiring this site bound virions after tryptic cleavage of site 1. This resuilt allowed the amount of site 1-specific antibodies to be determined in an antiserum by comparing its reactivity with virus and trypsin-cleaved virus. Antisera to poliovirus 3 Sabin strain (PS3) but not poliovirus 1 Sabin showed site 1 immunodominance, consistent with the frequency of isolation of site 1-specific monoclonal antibodies to these viruses. Cleavage of site 1 prior to immunization dramatically reduced the immunogenicity of this site in PS3. However, the antiserum against trypsin-cleaved PS3 still had a high neutralization titer, demonstrating that sites other than site 1 can elicit a neutralizing response to PS3. Other antisera to PS3 showed significant variability in the response to site 1, indicating that other factors, such as the genetic background of inbred mouse strains, the species immunized, and the immunization protocol, also affect immunodominance. In particular, a serum from a human infant recently immunized with oral trivalent vaccine had little response to site 1.
Poliovirus provides an excellent model for the characterization of the humoral response to viral pathogens. Several strains of the virus (including the Sabin vaccine strains of all three serotypes and the parental neurovirulent strains of poliovirus 1 [Mahoney] and poliovirus 3 [Leon]) have been sequenced (8, (12) (13) (14) (15) ; the three-dimensional structure of the Mahoney strain of poliovirus 1 has recently been determined at high resolution by X-ray crystallographic methods (4) , and the neutralization sites of representative strains of all three serotypes of poliovirus have been mapped by sequencing variants which are resistant to neutralizing monoclonal antibodies (1, 2, 9, 9a, 10, 16). The sequence changes in these variants have been located on the three-dimensional structure determined by X-ray crystallographic studies and have been shown to map on four discrete sites on the surface of the virion (5) . Recent evidence suggests that two of these sites are linked (9a) . Interestingly, the relative importance of each of the three sites in the humoral response of mice to poliovirus appears to be a function of the serotype or strain of the virus or both. Thus, the majority of monoclonal antibodies to the Leon and Sabin strains of poliovirus 3 select for mutations in a 12-amino-acid site in virion protein VP1 (residues 89 to 100), which is part of the site designated site 1, whereas the majority of monoclonal antibodies to the Sabin and Mahoney strains of poliovirus 1 select for mutations in sites 2 and 3, which include residues in VP2 and VP3, respectively.
We previously showed that there is a unique trypsin cleavage site at Lys-99 of VP1 in the Sabin strain of poliovirus 1 (PS1) (3) . Cleavage at Lys-99 did not produce a significant decrease in infectivity and was shown not to affect the ability of a rabbit antiserum to neutralize PS1. We have now extended these studies to include seven antipoliovirus 1 monoclonal antibodies. Of the seven monoclonal antibodies tested, six had immunoprecipitation titers against virus and trypsin-cleaved virus which were indistinguishable. These six monoclonal antibodies induce mutations in sites 2 and 3 (Marie Chow, personal communication). The remaining monoclonal antibody (C3 [16] ) had a marked reduction in titer against trypsin-cleaved virus. This antibody (which was raised against heat-treated virions) is the only anti-poliovirus 1 monoclonal antibody which is known to induce mutations in the area of the trypsin cleavage site (R. Crainic, personal communication).
In our earlier communication, we also noted that the Sabin strain of poliovirus 3 (PS3) has a unique trypsin cleavage site in capsid protein VP1 which produced two fragments similar in size to those seen in PS1 (3) . By analogy with PS1, we argued that the cleavage site was at Arg-98 of VP1 in PS3. This prediction has now been confirmed by sequencing. The sequence of the amino terminus of the large fragment was Ala-Gln-Lys-Leu-Phe, as expected for residues 99 to 103 of VP1 (14) , thus establishing cleavage at Arg-98. There was no detectable leucine in the first sequencing cycle, indicating no detectable cleavage at Lys-101. Although neither the amino nor carboxy termini of the small (amino-terminal) fragment were sequenced, additional cleavages in the small fragment are unlikely, since the last basic residue in this fragment is Arg-81 and since residues 1 to 85 are buried in the interior of the virion (4) . Note that PS1 has two additional amino acids very near the N terminus of VP1 and thus, Lys-99 in PS1 is in an equivalent position to Thr-97 in PS3 (14, 15) .
Immunoprecipitation titers against virions and trypsincleaved virions were also determined for a panel of monoclonal antibodies against poliovirus 3 residues 286 to 288 of VP1) and is known to be insensitive to mutations in site 1 (9) .
Thus, trypsin cleavage disrupted the ability of all monoclonal antibodies known to require residues 89 to 100 of VP1 to bind to either poliovirus 1 or poliovirus 3. If one assumes that trypsin-cleavage affects antibodies in sera in a similar fashion, the titer of a serum against trypsin-cleaved virions should reflect the precipitating response to all sites on the virus except residues 89 to 100 of VP1. The relative immunoprecipitation titers of a serum against virions and trypsincleaved virions can thus be used to estimate the percentage of the precipitating response in the serum which is directed against residues 89 to 100 of VP1. Hyperimmune sera against PSI and PS3 were prepared in BALB/c mice. To assess the reproducibility of the experiments, we did three separate immunizations. In each case, four male mice each were immunized intraperitoneally with PS1 and PS3. The sera from the four mice in each experiment were pooled, and the immunoprecipitation titers against virions and trypsin-cleaved virions were determined ( Fig. 1 and Table 2 ). Several precautions were taken in determining these titers. Cleaved virions were derived from virions by trypsin cleavage, ensuring that the two antigens had exactly the same specific activity. Serum volumes necessary for 50% precipitation of antigen were determined with multiple serum dilutions over the range of 0 to 100% antigen precipitation. The titrations against virions and cleaved virions were performed in parallel to normalize for errors in the serum dilutions. Note that although the exact titers varied for the three independent immunizations, the ratios of the titers against virions and cleaved virions were highly reproducible. See Fig. 1 for typical immunoprecipitation data. CRanges for evaluation of the ratio of titers are 0 to 0.2 for + + + +, 0.2 to 0.4 for + + +, 0.4 to 0.6 for + +, 0.6 to0.8 for +, and 0.8 to 1.0 for ±. These ranges are about three-fold higher than the variability between experiments.
d Titers in parentheses are the titers after absorption of the indicated antiserum with trypsin-cleaved PS1 or PS3 virions. Antiserum was reacted with 3 p.g of cleaved virions per p.l of antiserum, the complexes were removed by centrifugation, and the antiserum was retitrated. In the case of PS1 antiserum, two such absorption cycles were necessary.
ically reduced the titer against cleaved virions without significantly reducing the titer against intact virions. We therefore concluded that the response to site 1 s'trongly dominates the precipitating response of BALB/c mice to PS3. These results clearly demonstrated that the difference in the dominance of residues 89 to 100 in VP1 in Mahoneyderived strains of poliovirus 1 and Leon-derived strains of poliovirus 3 which was originally observed in the monoclonal antibody mutation experiments is reflected in sera and is therefore not an artifact of monoclonal antibody production and selection.
There are several possible explanations for the typespecific differences in the dominance of site 1 in mice. First, the dominance of site 1 in poliovirus 3 may reflect the lack of immunogenicity of sites other'than residues 89 to 100 of VP1 in Leon-derived strains of poliovirus 3. Second, the difference in dominance may reflect structural differences in poliovirus 1 and poliovirus 3 which cause increased immunogenicity of residues 89 to 100 in Leon-derived strains of poliovirus 3. Third, the dominance may be a reflection of host factors which control the relative immunogenicity of the sites on the viruses.
To assess the immunogenicity of sites other than residues 89 to 100 of VP1 in poliovirus 3, we used trypsin-cleaved PS3 virions to produce hyperimmune serum in BALB/c mice. The serum had a high neutralization titer against PS3 (106 PFU/ml of serum). Under identical conditions, the serum to PS3 from immunization group 1 ( Fig. 2 for immunoprecipitation data for C57BL/6, SJL/J, horse, and human antisera to PS3.
b Evaluations were made as described in Table 2 , footnote c. c Mice were immunized as described in Table 2 , footnote a. d Horse antiserum was from the American Type Culture Collection (NIAID V-003-501-560). Poliovirus 3 strain Leon and PS3 have identical amino acid sequences in site 1.
Monkeys were immunized intramuscularly with about 108 PFU of virus. For PS1, immunizations were done on weeks 0, 2, and 8, and serum was taken on week 13. For PS3, immunizations were done on weeks 0, 2, 9, and 13, and serum was taken on week 15.
f Serum was taken from a 10-month-old healthy male immunized with trivalent oral poliovaccine at 3 and 5 months of age. Significant vaccine-induced immunoglobulin G levels are expected at this stage of a live-poliovirus vaccination protocol (11) . tion titers against cleaved and intact virions in a number of inbred strains of mice and in several outbred species of animals, including horses, monkeys, and humans. Representative titrations are shown in Fig. 2 , and the results are summarized in Table 3 .
The results with the inbred strains of mice indicated that although residues 89 to 100 of VP1 dominated the response to PS3 in all strains of mice tested, the degree of dominance varied greatly from strain to strain (the ratio of titers varied from 0.06 for C57BL/6 mice to 0.30 for SJL/J mice). The experiment was repeated with C57BL/6 and SJL/J mice (Table 3 , rows 7 and 8) . This repeat experiment used a second preparation of virus which, for unknown reasons, yields uniformly higher ratios of titers. Nonetheless, the dependence of immunodominance in the response to PS3 on mouse strains was clearly reproduced.
Preliminary experiments with congenic mice, which differ genetically only at the H-2 locus, did not reveal a linkage of dominance to the H-2 haplotype (data not shown). Finally, it is of some interest to note that there was little response to either PS1 or PS3 in T-cell-deficient nude BALB/c mice (titers, <104) (data not shown). This latter result argues that T-cell functions are required for an efficient murine response to poliovirus and suggests that factors involved in the presentation of antigens contribute to the immune response.
In contrast to the results with mice, poliovirus 3 induced a small response to site 1 in other species (horses, monkeys, and humans) ( Fig. 2C and D PS1 induced little response to residues 89 to 100 of VP1 in any of the strains of mice tested. All strains of mice tested with PS3 were also tested with PS1, but only two are listed for brevity (Table 3 , rows 12 and 13). Consistent with the observations with PS1 in mice, other species (monkeys and humans) showed only a minor precipitating response to residues 89 to 100 of VP1 in PS1 (Table 3, rows 14 and 15) .
In summary, the data presented here confirm and extend the observation made with monoclonal antibodies that a single 12-amino-acid loop (residues 89 to 100 of VP1) dominates the murine immune response to Leon-derived strains of poliovirus 3 but not the Mahoney-derived strains of poliovirus 1 . The results also demonstrate that the dominance of this site in poliovirus 3 is not due to a lack of immunogenicity of other sites and that the control of dominance may be complex, including factors such as the species and genetic background of the animal immunized or the route of administration or both. Thus, considerable caution must be exercised in attempts to extrapolate the mapping of the immune response to viral antigens from data generated from inbred lines of a single species. The results further suggest the possible importance of the proteolytic processing of viral antigens in modulating the fine spectrum of the immune response to viral antigens. These observations may be of particular importance in ongoing attempts to design new attenuated vaccines for poliovirus and related viruses by recombinant DNA methods. Finally, the results suggest that the protecting immune response generated by oral administration of the live PSI and PS3 vaccines is directed against sites other than residues 89 to 100 of VP1.
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